Waterman E A, Kemp E H, Gawkrodger D J, Watson P F, Weetman A P
Division of Clinical Sciences (North), University of Sheffield, UK.
Clin Exp Immunol. 2002 Sep;129(3):527-32. doi: 10.1046/j.1365-2249.2002.01949.x.
Recent studies have demonstrated the presence of circulating MelanA (MART1)-specific cytotoxic T lymphocytes in a significant number of vitiligo patients when compared to control subjects. High levels of the skin-homing receptor cutaneous lymphocyte-associated antigen were expressed on the T cells and their frequency correlated with the extent of depigmentation and disease activity in the vitiligo patients. The present study was designed to examine vitiligo patient sera for the presence of autoantibodies to MelanA. The incidence of autoantibodies to MelanA in patients with vitiligo (n = 51) and in healthy individuals (n = 20) was examined using a radiobinding assay with 35S]-labelled MelanA and using Western blot analysis with a glutathione S-transferase (GST)-MelanA fusion protein. Autoantibodies to MelanA could not be detected in any of the vitiligo patient sera or control sera analysed using either of these detection systems. It is therefore possible that MelanA only induces cellular rather than humoral autoreactivity in vitiligo.
与对照受试者相比，最近的研究表明，相当数量的白癜风患者体内存在循环的黑色素瘤抗原A（MART1）特异性细胞毒性T淋巴细胞。T细胞上表达了高水平的皮肤归巢受体皮肤淋巴细胞相关抗原，其频率与白癜风患者的色素脱失程度和疾病活动度相关。本研究旨在检测白癜风患者血清中是否存在抗黑色素瘤抗原A的自身抗体。采用³⁵S标记的黑色素瘤抗原A进行放射结合试验，并使用谷胱甘肽S-转移酶（GST）-黑色素瘤抗原A融合蛋白进行蛋白质印迹分析，检测了白癜风患者（n = 51）和健康个体（n = 20）中抗黑色素瘤抗原A自身抗体的发生率。使用这两种检测系统分析的任何白癜风患者血清或对照血清中均未检测到抗黑色素瘤抗原A的自身抗体。因此，在白癜风中，黑色素瘤抗原A可能仅诱导细胞而非体液自身反应性。
